Switzerland· 66510001
Vosevi, Filmtabletten
A sofosbuvir, velpatasvir and voxilaprevir product containing sofosbuvirum, velpatasvirum, voxilaprevirum, registered in Switzerland by Gilead Sciences Switzerland Sàrl and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Sofosbuvir, velpatasvir and voxilaprevir is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AP56 (sofosbuvir, velpatasvir and voxilaprevir), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 10 of them publish a price we can compare per daily dose
Sofosbuvir, velpatasvir and voxilaprevir · ATC J05AP56
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of sofosbuvir, velpatasvir and voxilaprevir costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), the median price runs from $447.39 in Switzerland to $1097.10 in Italy — a ×2.5 gap.
- Switzerland: $447.39 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Sofosbuvir, velpatasvir and voxilaprevir · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- IT Italy$1097.10
- CH Switzerland$447.39
The record
At a glance
Swissmedic (Switzerland)- Active substance
- sofosbuvirum, velpatasvirum, voxilaprevirum
- Manufacturer
- Gilead Sciences Switzerland Sàrl
- Country
- Switzerland (CH)
- ATC code
- J05AP56
- ATC class
- Sofosbuvir, velpatasvir and voxilaprevir
- Defined daily dose
- 0.4 g, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680665100012Fl 28 StkCHF 10389
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sofosbuvir, velpatasvir and voxilaprevir in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsVosevi 200 mg/50 mg/50 mg, filmomhulde tablettenGilead Sciences Ireland UC
- FinlandVoseviGilead Sciences Ireland UC
- PolandVoseviGilead Sciences Ireland UC
- SwedenVosevi 200 mg/50 mg/50 mg Filmdragerad tablettGilead Sciences Ireland UC
- CzechiaVOSEVIGilead Sciences Ireland UC, Carrigtohill
- IrelandVosevi 200 mg/50 mg/50 mg film-coated tabletsGilead Sciences Ireland UC
- IcelandVoseviGilead Sciences Ireland UC*
- United StatesVoseviGilead Sciences, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vosevi
- Liechtenstein · Vosevi
- Norway · Vosevi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7eefe817-e05d-4875-9fc6-06ae489b5f22 GET /v1/drugs/7eefe817-e05d-4875-9fc6-06ae489b5f22?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "sofosbuvirum 400 mg + velpatasvirum 100 mg + voxilaprevirum 100 mg",
"valid_from": "2024-10-01",
"limitations": "[{\"description\":\"Zur Behandlung der chronischen Hepatitis-C-Virus (HCV)-Infektion bei Erwachsenen ohne Zirrhose oder mit kompensierter Zirrhose bei denen ein vorheriges Behandlungsregime mit direkt wirkendem Virostatikum (direct-acting antiviral, DAA) gegen HCV, das einen NS5A-Inhibitor enthielt, versagt hat.<br> \\n• Bei allen Patienten sollte vor Beginn der Behandlung ein HBV-Screening durchgeführt werden. Patienten mit einer positiven HBV-Serologie sollten nach den aktuellen Richtlinien zur klinischen Praxis überwacht und behandelt werden.<br> \\n• Die maximale Vergütungsdauer pro Patient/in ist 12 Wochen (3 Packungen).<br> \\n• Die Verschreibung darf ausschliesslich durch Fachärzte für Gastroenterologie mit Träger des Schwerpunktes Hepatologie oder durch Fachärzte für Infektiologie erfolgen.<br>\\n<br>\\n\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2024-10-01\",\"validTo\":\"2026-09-30\"}]",
"galenic_form": "Filmtabl 400/100/100",
"therapeutic_area": null,
"sl_inclusion_date": "2024-10-01",
"self_retention_pct": 10
}See everything about sofosbuvir, velpatasvir and voxilaprevir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.